Abdulla A Damluji1,2, Michael Fabbro3, Richard H Epstein3, Stefan Rayer4, Ying Wang4, Mauro Moscucci5, Mauricio G Cohen6, John D Carroll7, John C Messenger7, Jon R Resar2, David J Cohen8, Matthew W Sherwood1, Christopher M O'Connor1, Wayne Batchelor1. 1. Inova Center of Outcomes Research, Inova Heart and Vascular Institute, Falls Church, VA (A.A.D., M.W.S., C.M.O., W.B.). 2. Division of Cardiology, Johns Hopkins University, Baltimore, MD (A.A.D., J.R.R.). 3. Department of Anesthesiology, University of Miami, FL (M.F., R.H.E.). 4. Bureau of Economic and Business Research, University of Florida, Gainesville, FL (S.R., Y.W.). 5. University of Michigan, Ann Arbor, MI (M.M.). 6. Cardiovascular Division, University of Miami, FL (M.G.C.). 7. Division of Cardiology, University of Colorado School of Medicine, Aurora, CO (J.D.C., J.C.M.). 8. University of Missouri-Kansas City School of Medicine, Kansas City, MO (D.J.C.).
Abstract
BACKGROUND: Restricting transcatheter aortic valve replacement (TAVR) to centers based on volume thresholds alone can potentially create unintended disparities in healthcare access. We aimed to compare the influence of population density in state of Florida in regard to access to TAVR, TAVR utilization rates, and in-hospital mortality. METHODS AND RESULTS: From 2011 to 2016, we used data from the Agency for Health Care Administration to calculate travel time and distance for each TAVR patient by comparing their home address to their TAVR facility ZIP code. Travel time and distance, TAVR rates, and mortality were compared across categories of low to high population density (population per square miles of land). Of the 6531 patients included, the mean (SD) age was 82 (9) years, 43% were female and 91% were White. Patients residing in the lowest category (<50/square miles) were younger, more likely to be men, and less likely to be a racial minority. Those residing in the lowest category density faced a longer unadjusted driving distances and times to their TAVR center (mean extra distance [miles]=43.5 [95% CI, 35.6-51.4]; P<0.001; mean extra time (minutes)=45.6 [95% CI, 38.3-52.9], P<0.001). This association persisted regardless of the methods used to determine population density. Excluding uninhabitable land, there was a 7-fold difference in TAVR utilization rates in the lowest versus highest population density regions (7 versus 45 per 100 000, P-for-pairwise-comparisons <0.001) and increase in TAVR in-hospital mortality (adjusted OR, 6.13 [95% CI, 1.97-19.1]; P<0.001). CONCLUSIONS: Older patients living in rural counties in Florida face (1) significantly longer travel distances and times for TAVR, (2) lower TAVR utilization rates, and (3) higher adjusted TAVR mortality. These findings suggest that there are trade-offs between access to TAVR, its rate of utilization, and procedural mortality, all of which are important considerations when defining institutional and operator requirements for TAVR across the country.
BACKGROUND: Restricting transcatheter aortic valve replacement (TAVR) to centers based on volume thresholds alone can potentially create unintended disparities in healthcare access. We aimed to compare the influence of population density in state of Florida in regard to access to TAVR, TAVR utilization rates, and in-hospital mortality. METHODS AND RESULTS: From 2011 to 2016, we used data from the Agency for Health Care Administration to calculate travel time and distance for each TAVR patient by comparing their home address to their TAVR facility ZIP code. Travel time and distance, TAVR rates, and mortality were compared across categories of low to high population density (population per square miles of land). Of the 6531 patients included, the mean (SD) age was 82 (9) years, 43% were female and 91% were White. Patients residing in the lowest category (<50/square miles) were younger, more likely to be men, and less likely to be a racial minority. Those residing in the lowest category density faced a longer unadjusted driving distances and times to their TAVR center (mean extra distance [miles]=43.5 [95% CI, 35.6-51.4]; P<0.001; mean extra time (minutes)=45.6 [95% CI, 38.3-52.9], P<0.001). This association persisted regardless of the methods used to determine population density. Excluding uninhabitable land, there was a 7-fold difference in TAVR utilization rates in the lowest versus highest population density regions (7 versus 45 per 100 000, P-for-pairwise-comparisons <0.001) and increase in TAVR in-hospital mortality (adjusted OR, 6.13 [95% CI, 1.97-19.1]; P<0.001). CONCLUSIONS: Older patients living in rural counties in Florida face (1) significantly longer travel distances and times for TAVR, (2) lower TAVR utilization rates, and (3) higher adjusted TAVR mortality. These findings suggest that there are trade-offs between access to TAVR, its rate of utilization, and procedural mortality, all of which are important considerations when defining institutional and operator requirements for TAVR across the country.
Entities:
Keywords:
accreditation; hospital mortality; minority; population density; registries
Authors: Krisda H Chaiyachati; Rebecca A Hubbard; Alyssa Yeager; Brian Mugo; Stephanie Lopez; Elizabeth Asch; Catherine Shi; Judy A Shea; Roy Rosin; David Grande Journal: JAMA Intern Med Date: 2018-03-01 Impact factor: 21.873
Authors: Joseph E Bavaria; Carl L Tommaso; Ralph G Brindis; John D Carroll; G Michael Deeb; Ted E Feldman; Thomas G Gleason; Eric M Horlick; Clifford J Kavinsky; Dharam J Kumbhani; D Craig Miller; A Allen Seals; David M Shahian; Richard J Shemin; Thoralf M Sundt; Vinod H Thourani Journal: J Am Coll Cardiol Date: 2018-07-18 Impact factor: 24.094
Authors: Barbara A Blanco; Anai N Kothari; Robert H Blackwell; Sarah A Brownlee; Ryan M Yau; John P Attisha; Yoshiki Ezure; Sam Pappas; Paul C Kuo; Gerard J Abood Journal: Surgery Date: 2016-11-14 Impact factor: 3.982
Authors: Darren Mylotte; Ruben L J Osnabrugge; Stephan Windecker; Thierry Lefèvre; Peter de Jaegere; Raban Jeger; Peter Wenaweser; Francesco Maisano; Neil Moat; Lars Søndergaard; Johan Bosmans; Rui C Teles; Giuseppe Martucci; Ganesh Manoharan; Eulogio Garcia; Nicolas M Van Mieghem; A Pieter Kappetein; Patrick W Serruys; Ruediger Lange; Nicolo Piazza Journal: J Am Coll Cardiol Date: 2013-05-15 Impact factor: 24.094
Authors: Ashwin S Nathan; Lin Yang; Nancy Yang; Lauren A Eberly; Sameed Ahmed M Khatana; Elias J Dayoub; Sreekanth Vemulapalli; Howard Julien; David J Cohen; Brahmajee K Nallamothu; Suzanne J Baron; Nimesh D Desai; Wilson Y Szeto; Howard C Herrmann; Peter W Groeneveld; Jay Giri; Alexander C Fanaroff Journal: JAMA Cardiol Date: 2022-02-01 Impact factor: 14.676
Authors: Ashwin S Nathan; Lin Yang; Nancy Yang; Sameed Ahmed M Khatana; Elias J Dayoub; Lauren A Eberly; Sreekanth Vemulapalli; Suzanne J Baron; David J Cohen; Nimesh D Desai; Joseph E Bavaria; Howard C Herrmann; Peter W Groeneveld; Jay Giri; Alexander C Fanaroff Journal: Circ Cardiovasc Qual Outcomes Date: 2021-10-21
Authors: Dae Yong Park; Seokyung An; Jonathan M Hanna; Stephen Y Wang; Ana S Cruz-Solbes; Ajar Kochar; Angela M Lowenstern; John K Forrest; Yousif Ahmad; Michael Cleman; Abdulla Al Damluji; Michael G Nanna Journal: PLoS One Date: 2022-10-20 Impact factor: 3.752